AstraZeneca lung cancer drug combo boosts survival in late
Amgen's Imdelltra and AstraZeneca's Imfinzi combo improved survival in a late-stage lung cancer trial. The combo also enhanced progression-free survival and response rate. Imdelltra, approved for extensive-stage small-cell lung cancer, generated $513M in 2023 sales for Amgen, with cancer therapies making up 23% of its total sales. AstraZeneca has faced recent setbacks in other drug trials.
How this was made
The 30-second read
Why it matters
The data could reshape revenue forecasts for both companies and influence analyst ratings.
Market read
Positive trial outcomes are likely to drive short‑term buying interest and longer‑term valuation adjustments for both stocks.
What to watch
Potential competition from other emerging immunotherapies and the need for further confirmatory trials.
Background
The article reports first disclosure of late-stage trial results for an Amgen‑AstraZeneca combination in extensive‑stage small‑cell lung cancer.
Ticker impact
Amgen's immunotherapy Imdelltra showed improved overall survival in a late-stage small-cell lung cancer trial.
upward pressure over the next few weeks
First disclosure of pivotal trial results; Amgen's cancer portfolio is a key revenue driver.
AstraZeneca's drug Imfinzi, when combined with Amgen's therapy, improved survival in the same trial.
moderate upside as investors reassess pipeline potential
New efficacy data for an existing marketed product can lift revenue expectations.
Market effects
Strengthens the oncology sector outlook, especially for bispecific antibodies and checkpoint inhibitors.
Positive for US biotech investors; may influence European markets where AZN is also listed.
Highlights continued innovation in cancer immunotherapy worldwide.
Counterpoint
If the combination faces regulatory hurdles or pricing pressure, the upside could be limited.
Key entities
- CompanyAmgen
US biotech firm developing Imdelltra.
- CompanyAstraZeneca
Global pharma company with Imfinzi.
